Cargando…

Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China

OBJECTIVE: This study aimed to assess the efficacy and safety of 2 Janus kinase (JAK) inhibitors (jakinibs) tofacitinib and ruxolitinib in the treatment of type I interferonopathies patients including STING-associated vasculopathy with onset in infancy (SAVI), Aicardi-Goutières syndrome (AGS), and s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Wendao, Wang, Wei, Zhong, Linqing, Gou, Lijuan, Wang, Changyan, Ma, Jingran, Quan, Meiying, Jian, Shan, Tang, Xiaoyan, Zhang, Yu, Wang, Lin, Ma, Mingsheng, Song, Hongmei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995420/ https://www.ncbi.nlm.nih.gov/pubmed/35418997 http://dx.doi.org/10.3389/fimmu.2022.825367

Ejemplares similares

Chronic active Epstein–Barr virus infection as the initial symptom in a Janus kinase 3 deficiency child: Case report and literature review
por: Zhong, Linqing, et al.
Publicado: (2017)

Familial Mediterranean Fever in Chinese Children: A Case Series
por: Li, Ji, et al.
Publicado: (2019)

Clinical and genetic spectrum of 14 cases of NLRP3-associated autoinflammatory disease (NLRP3-AID) in China and a review of the literature
por: Zhou, Yu, et al.
Publicado: (2022)

Efficacy and safety of thalidomide in children with monogenic autoinflammatory diseases: a single-center, real-world-evidence study
por: Zhang, Caihui, et al.
Publicado: (2023)

Single-Center Overview of Pediatric Monogenic Autoinflammatory Diseases in the Past Decade: A Summary and Beyond
por: Wang, Wei, et al.
Publicado: (2020)

The association of MEFV gene mutations with the disease risk and severity of systemic juvenile idiopathic arthritis
por: Zhong, Linqing, et al.
Publicado: (2020)

RAS-associated Autoimmune Leukoproliferative disease (RALD) manifested with early-onset SLE-like syndrome: a case series of RALD in Chinese children
por: Wang, Wei, et al.
Publicado: (2019)

Myasthenia Gravis: An Acquired Interferonopathy?
por: Payet, Cloé A., et al.
Publicado: (2022)

Lung involvement in monogenic interferonopathies
por: Cazzato, Salvatore, et al.
Publicado: (2020)

Type I Interferonopathies in Childhood
por: Haşlak, Fatih, et al.
Publicado: (2023)

Tocilizumab reduces the unmanageable inflammatory reaction of a patient with Aicardi-Goutières syndrome type 7 during treatment with ruxolitinib
por: Wang, Wei, et al.
Publicado: (2023)

Type I interferonopathies in pediatric rheumatology
por: Volpi, Stefano, et al.
Publicado: (2016)

Type I Interferonopathies in Children: An Overview
por: d'Angelo, Debora M., et al.
Publicado: (2021)

The type I interferonopathies: 10 years on
por: Crow, Yanick J., et al.
Publicado: (2021)

Clinical phenotypes and prognosis of cytomegalovirus infection in the pediatric systemic lupus erythematosus: a longitudinal analysis
por: Zhang, Tianyu, et al.
Publicado: (2023)

MEFV M694V mutation has a role in susceptibility to ankylosing spondylitis: A meta-analysis
por: Zhong, Linqing, et al.
Publicado: (2017)

Monogenic interferonopathy presenting as CMV infection in infancy
por: Schütz, C, et al.
Publicado: (2015)

Selective immunoglobulin A deficiency (SIgAD) primarily leads to recurrent infections and autoimmune diseases: A retrospective study of Chinese patients in the past 40 years
por: Wang, Wei, et al.
Publicado: (2019)

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
por: Sanchez, Gina A. Montealegre, et al.
Publicado: (2018)

Covid-19–Associated Myopathy Caused by Type I Interferonopathy
por: Manzano, Giovanna S., et al.
Publicado: (2020)

Identification of type I interferonopathies using blood interferon signature: the experience of a pediatric rheumatology center
por: Volpi, S, et al.
Publicado: (2015)

The Janus kinases (Jaks)
por: Yamaoka, Kunihiro, et al.
Publicado: (2004)

Janus Kinases in Leukemia
por: Raivola, Juuli, et al.
Publicado: (2021)

ZBP1 contributes to interferonopathies caused by impaired ADAR1 function
por: Fang, Xiuwu, et al.
Publicado: (2022)

Multidimensional definition of the interferonopathy of Down syndrome and its response to JAK inhibition
por: Galbraith, Matthew D., et al.
Publicado: (2023)

Suppression of TREX1 deficiency-induced cellular senescence and interferonopathies by inhibition of DNA damage response
por: Du, Hekang, et al.
Publicado: (2023)

Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies
por: Kim, Hanna, et al.
Publicado: (2020)

Interferonopathies masquerading as non-Mendelian autoimmune diseases: pattern recognition for early diagnosis
por: Gagne, Samuel, et al.
Publicado: (2023)

Itch and Janus Kinase Inhibitors
por: HAN, Yujin, et al.
Publicado: (2023)

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor
por: Singer, Jack W, et al.
Publicado: (2016)

A case series of acne following Janus kinase inhibitors in patients with atopic dermatitis
por: Lee, Sang-Doo, et al.
Publicado: (2022)

HDAC stimulates gene expression through BRD4 availability in response to IFN and in interferonopathies
por: Marié, Isabelle J., et al.
Publicado: (2018)

Clinical spectrum and currently available treatment of type I interferonopathy Aicardi–Goutières syndrome
por: Dell’Isola, Giovanni Battista, et al.
Publicado: (2023)

Human RELA dominant-negative mutations underlie type I interferonopathy with autoinflammation and autoimmunity
por: Moriya, Kunihiko, et al.
Publicado: (2023)

Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne
por: BALLANGER, Fabienne, et al.
Publicado: (2023)

Azeliragon ameliorates Alzheimer's disease via the Janus tyrosine kinase and signal transducer and activator of transcription signaling pathway
por: Yang, Lijuan, et al.
Publicado: (2021)

Janus kinase inhibitors: jackpot or potluck?
por: Pavithran, Keechilat, et al.
Publicado: (2012)

Janus Kinase Inhibitors and Cell Therapy
por: Assal, Amer, et al.
Publicado: (2021)

Type I interferonopathies with novel compound heterozygous TREX1 mutations in two siblings with different symptoms responded to tofacitinib
por: Zhang, Shiyu, et al.
Publicado: (2021)

Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals
por: Melikhov, Oleg, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q45oira940b7gp78nu7mgehu0s